EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations

Federica Attaianese, Giulia Carreras, Sandra Trapani, Ilaria Alberti, Maurizio Aricò, Marina Attanasi, Giulia Bertolucci, Silvia Bressan, Désirée Caselli, Veronica Casotto, Salvatore Cazzato, Francesco Chiarelli und 32 weitere

JAMA Pediatrics · 01.07.2026 · 180 (7) · 783

DOI: 10.1001/jamapediatrics.2026.0657 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Pediatrics, erschienen am 01.07.2026. Verfasst von Federica Attaianese und 43 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Unit, Meyer Children's Hospital IRCCS, Florence, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antiviral Agents, Hospitalization, Respiratory Syncytial Virus Infections. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants and young children, imposing a substantial burden on health care systems. Nirsevimab, a long-acting monoclonal antibody, has shown high efficacy in clinical trials, and modeling studies suggest it may be cost-effective; however, real-world evidence on its cost-effectiveness in European health care settings remains limited.

Objective

To evaluate the real-world cost-effectiveness of nirsevimab immunization in preventing pediatric hospitalizations due to RSV. Design, Setting, and Participants This multicenter, observational, real-world cost-effectiveness analysis was conducted between October 1, 2022, and March 31, 2025. Precampaign data were modeled using Poisson regression models to estimate expected hospitalizations in the absence of immunization. Data were gathered from 19 pediatric hospitals distributed across 11 Italian regions, from northern to southern areas. Included were all pediatric hospitalizations with RSV-specific International Classification of Diseases, Ninth Revision, Clinical Modification discharge diagnoses recorded at participating hospitals between October 1, 2022, and March 31, 2025. Exposures Regional nirsevimab immunization campaigns with varying start dates and eligibility criteria, implemented between October 2024 and January 2025. Main Outcomes and Measures Effectiveness, expressed as hospitalizations averted (ΔE), and incremental costs (ΔC) were estimated from the Italian National Health Service perspective. Cost-effectiveness ratios (CERs = ΔC/ΔE) were calculated for each center.

Results

During the 2024 to 2025 season, 5924 RSV-related hospitalizations were recorded in children 18 years and younger across 19 centers. Observed admissions were consistently lower than model-based counterfactual predictions in most centers. Immunization averted between 6 and 151 admissions per center, corresponding to a rate of 83 and 1162 per 100 000 children. Incremental costs were negative in most centers, indicating cost savings ranging from −€10 924 (US $12 562.60) to −€266 954 (US $306 997.10) per center. Corresponding cost-effectiveness ratios were negative (−€1071 [US $1231.65] and −€1682 [(US $1934.30]), reflecting a cost-saving intervention. In 2 centers with late initiation and restricted eligibility, immunization was associated with higher costs relative to the number of hospitalizations prevented, with incremental costs of €19 715 (US $22 672.25) and €81 454 (US $93 672.10). Sensitivity analyses confirmed the robustness of results. Conclusions and Relevance Results of this Italian multicenter, real-world economic evaluation suggest that nirsevimab immunization was both clinically effective and cost saving from a health system perspective. Timing and eligibility of immunization strongly influenced cost-effectiveness, highlighting the importance of early and broad rollout strategies to maximize clinical and economic benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntiviral AgentsHospitalizationRespiratory Syncytial Virus InfectionsChild, PreschoolFemaleHumansInfantMaleCost-Effectiveness AnalysisItaly

Substanzen

Antibodies, Monoclonal, HumanizedAntiviral Agents

Autor:innen und Institutionen

  • Pediatric Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Meyer Children's Hospital IRCCS, Florence, Italy.
  • Department of Health Science, University of Florence, Florence, Italy.
  • IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Pediatric Unit, S. Spirito Hospital, Azienda Sanitaria Locale di Pescara, Pescara, Italy.
  • Department of Pediatrics, University of Chieti, Chieti, Italy.

Zitieren

APA

Attaianese, F., Carreras, G., Trapani, S., Alberti, I., Aricò, M., Attanasi, M., Bertolucci, G., Bressan, S., Caselli, D., Casotto, V., Cazzato, S., Chiarelli, F., Felici, E., Frusciante, A., Galeone, M. A., Garazzino, S., Giannattasio, A., Gitto, E., Guerriero, A., …, & Indolfi, G. (2026). Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations. JAMA Pediatrics, 180(7), 783. https://doi.org/10.1001/jamapediatrics.2026.0657

Vancouver

Attaianese F, Carreras G, Trapani S, Alberti I, Aricò M, Attanasi M, et al. Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations. JAMA Pediatrics. 2026;180(7):783. doi:10.1001/jamapediatrics.2026.0657

BibTeX
@article{Attaianese2026,
  author = {Attaianese, Federica and Carreras, Giulia and Trapani, Sandra and Alberti, Ilaria and Aricò, Maurizio and Attanasi, Marina and Bertolucci, Giulia and Bressan, Silvia and Caselli, Désirée and Casotto, Veronica and Cazzato, Salvatore and Chiarelli, Francesco and Felici, Enrico and Frusciante, Anna and Galeone, Maria Antonia and Garazzino, Silvia and Giannattasio, Antonietta and Gitto, Eloisa and Guerriero, Antonio and Guida, Fiorentina and Iudica, Giovanna and Lanari, Marcello and Mandato, Claudia and Manzini, Alice and Martelli, Gaia and Milani, Gregorio Paolo and Moriondo, Maria and Notarangelo, Lucia Dora and Nunziata, Felice and Pellegrino, Roberta and Peroni, Diego and Piccotti, Emanuela and Ponticiello, Eduardo and Ricci, Silvia and Rulli, Immacolata and Savoia, Fabio and Silvestro, Erika and Sisto, Antonella and Soro, Federica and Tonetto, Stefania and Zago, Alessandro and Dani, Carlo and Azzari, Chiara and Indolfi, Giuseppe},
  title = {Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations},
  journal = {JAMA Pediatrics},
  year = {2026},
  volume = {180},
  number = {7},
  pages = {783},
  doi = {10.1001/jamapediatrics.2026.0657}
}
Kostenlos starten →